We plan to pursue our studies of factors that affect activity and inducibility of the microsomal ethanol oxidizing systems (MEOS) and associated functions, and hence their pathologic role in alcohol-induced liver injury. We will take advantage of the availability of liver specimens reflecting a large spectrum of human disease, and subject them to Western blot and PCR analysis for P4502E1 (2E1) protein and mRNA, respectively. We will first determine how the induction of microsomal 2E1 is regulated in man, with focus on possible roles of dose and type of alcoholic beverage, age and associated medications and/or deficiencies. We will also asses the role of dietary lipids, especially the species of phosphatidylcholine, in the activity of MEOS in vitro and its inducibility in vivo after chronic ethanol consumption. Specifically, we will evaluate in vitro how the fatty acid composition of the phospholipids may affect 2E1 catalytic activity. In vivo, we will determine how changes in dietary lipids alter the activity of enzymes (including 2E1) in liver microsomes and how the latter correlates with changes in phospholipid composition. The studies will be conducted in our experimental models of alcoholic liver injury in rodents and nonhuman primates and corroborated in human liver tissue, which we will obtain from a parallel study evaluating the effects of supplementation of dietary phospholipids on the outcome of alcoholic liver disease. Associated changes in microsomal phosphatidylethanolamine methyltransferase activity and membrane fluidity will be determined. At present, measurement of 2E1 activity requires liver tissue. However, since 2E1 metabolizes not only ethanol but also chlorozoxazone (CZX), a widely used drug, the suitability of CZX clearance in vivo as a marker of 2E1 induction will be evaluated. These studies will be extended to P4501A2(1A2), found to be able to sustain ethanol metabolism, inducible by factors commonly present in the heavy drinker (smoking, omeprazole treatment) and capable of activating carcinogens. A potentially important factor that may affect 2E1 and 1A2 activity is the extent of adduct formation between the proteins and acetaldehyde. The potential impact of this adduction on the catalytic conversion of ethanol to acetaldehyde, and other 2E1 and 1A2 mediated activities, will be investigated. The planned studies, by revealing some of the determining factors of enzyme activity, may provide the information needed to minimize ethanol's toxicity, or that resulting from the activation of other hepatotoxins. Finally, we will also evaluate the interaction of ethanol with microsomal P450s (especially P4502C8, 1A2 and also 3A3/4) in retinoid metabolism and hepatic retinol depletion, which may contribute to the increased incidence of various cancers in the alcoholic. The broad aim of our proposed studies is to define biochemical differences between heavy drinkers and more moderate consumers. We will focus on the microsomal cytochrome P450 system and its changes secondary to drinking, which have been shown to alter the response of the alcoholic to ethanol and other hepatotoxic agents and even nutrients. Such information is aimed at elucidating key aspects of alcohol mediated pathology in a way which may eventually affect alcohol related medical complications, their prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
5R01AA005934-14
Application #
2855740
Study Section
Biochemistry, Physiology and Medicine Subcommittee (ALCB)
Program Officer
Isaki, Leslie
Project Start
1983-07-01
Project End
2001-06-30
Budget Start
1999-01-01
Budget End
2001-06-30
Support Year
14
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Ren, Chaoling; Paronetto, Fiorenzo; Mak, Ki M et al. (2003) Cytokeratin 7 staining of hepatocytes predicts progression to more severe fibrosis in alcohol-fed baboons. J Hepatol 38:770-5
Ponomarenko, Yelena; Leo, Maria Anna; Kroll, Werner et al. (2002) Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol Alcohol 37:252-5
Baraona, Enrique; Shoichet, Lilia; Navder, Khursheed et al. (2002) Mediation by nitric oxide of the stimulatory effects of ethanol on blood flow. Life Sci 70:2987-95
Oneta, Carl M; Lieber, Charles S; Li, JunJie et al. (2002) Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J Hepatol 36:47-52
Baraona, E; Abittan, C S; Dohmen, K et al. (2001) Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 25:502-7
Lieber, C S (2001) Liver diseases by alcohol and hepatitis C: early detection and new insights in pathogenesis lead to improved treatment. Am J Addict 10 Suppl:29-50
Salmela, K S; Tsyrlov, I B; Lieber, C S (2001) Azide inhibits human cytochrome P -4502E1, 1A2, and 3A4. Alcohol Clin Exp Res 25:253-60
Lieber, C S (2001) Alcoholic liver injury: pathogenesis and therapy in 2001. Pathol Biol (Paris) 49:738-52
Aleynik, M K; Lieber, C S (2001) Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome P4502E1. Biochem Biophys Res Commun 288:1047-51
Ni, R; Leo, M A; Zhao, J et al. (2001) Toxicity of beta-carotene and its exacerbation by acetaldehyde in HepG2 cells. Alcohol Alcohol 36:281-5

Showing the most recent 10 out of 116 publications